$BLNC
Balance Labs, Inc.

2024 Q4 Form 10-Q Financial Statement

#000149315224046598 Filed on November 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $34.48K
YoY Change 38.75%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $83.69K $34.48K
YoY Change 142.72% 38.73%
Operating Profit -$83.69K -$34.48K
YoY Change 142.72% -180.85%
Interest Expense $57.51K
YoY Change 0.0%
% of Operating Profit
Other Income/Expense, Net -$109.1K -$34.26K
YoY Change 218.63% -81.51%
Pretax Income -$68.74K
YoY Change -51.79%
Income Tax
% Of Pretax Income
Net Earnings -$192.8K -$68.74K
YoY Change 180.55% -51.79%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 $0.00
Diluted Earnings Per Share -$0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 21.67M shares 21.67M shares 21.67M shares
Diluted Shares Outstanding 21.67M shares 21.67M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $110.3K $324.3K
YoY Change -65.98% -37.06%
Cash & Equivalents $30.41K $145.6K
Short-Term Investments $79.94K $178.7K
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables $0.00
Total Short-Term Assets $110.3K $324.3K
YoY Change -65.98% 3.22%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $110.3K $324.3K
Total Long-Term Assets $0.00 $0.00
Total Assets $110.3K $324.3K
YoY Change -65.98% -42.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.271M
YoY Change 149.12%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.699M
YoY Change 0.0%
Long-Term Debt Due $280.0K
YoY Change 0.0%
Total Short-Term Liabilities $5.064M $4.250M
YoY Change 19.15% 5.0%
LONG-TERM LIABILITIES
Long-Term Debt $488.7K
YoY Change 2.38%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $488.7K
YoY Change 2.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.064M $4.250M
Total Long-Term Liabilities $488.7K
Total Liabilities $5.064M $4.738M
YoY Change 6.87% 4.72%
SHAREHOLDERS EQUITY
Retained Earnings -$5.766M -$5.226M
YoY Change 10.32% 9.4%
Common Stock $2.167K $2.167K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.953M -$4.414M
YoY Change
Total Liabilities & Shareholders Equity $110.3K $324.3K
YoY Change -65.98% -42.06%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$192.8K -$68.74K
YoY Change 180.55% -51.79%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$36.78K
YoY Change -172.12%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -36.78K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -36.78K
YoY Change -187.63%
FREE CASH FLOW
Cash From Operating Activities -$36.78K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Entity File Number
EntityFileNumber
333-202959
dei Entity Address City Or Town
EntityAddressCityOrTown
Miami Beach
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21674000 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001632121
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 701
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-192837 usd
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
dei Entity Registrant Name
EntityRegistrantName
BALANCE LABS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1146785
dei Entity Address Address Line1
EntityAddressAddressLine1
407 Lincoln Road
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33139
dei City Area Code
CityAreaCode
(305)
dei Local Phone Number
LocalPhoneNumber
907-7600
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21674000 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30407 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112809 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
79936 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
107912 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
110343 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
220721 usd
CY2024Q3 us-gaap Assets
Assets
110343 usd
CY2023Q4 us-gaap Assets
Assets
220721 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1643447 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1381849 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5063706 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4763604 usd
CY2024Q3 us-gaap Liabilities
Liabilities
5063706 usd
CY2023Q4 us-gaap Liabilities
Liabilities
4763604 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21674000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21674000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21674000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21674000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
2167 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2167 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
810048 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
810048 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5765578 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5355098 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4953363 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4542883 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
110343 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
220721 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4557 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8005 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11779 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19536 usd
CY2024Q3 us-gaap Professional Fees
ProfessionalFees
32293 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
11274 usd
us-gaap Professional Fees
ProfessionalFees
56838 usd
us-gaap Professional Fees
ProfessionalFees
50249 usd
CY2024Q3 us-gaap Salaries And Wages
SalariesAndWages
46838 usd
CY2023Q3 us-gaap Salaries And Wages
SalariesAndWages
15200 usd
us-gaap Salaries And Wages
SalariesAndWages
138659 usd
us-gaap Salaries And Wages
SalariesAndWages
42141 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
83688 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
34479 usd
us-gaap Operating Expenses
OperatingExpenses
207276 usd
us-gaap Operating Expenses
OperatingExpenses
111926 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-83688 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-34479 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-207276 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-111926 usd
CY2024Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-47746 usd
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
23250 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-27976 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
29894 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
61403 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
57506 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
175228 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
170136 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-109149 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-34256 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-203204 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-140242 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-192837 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-68735 usd
us-gaap Net Income Loss
NetIncomeLoss
-410480 usd
us-gaap Net Income Loss
NetIncomeLoss
-252768 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21674000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21674000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21674000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21674000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21674000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21674000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21674000 shares
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4760526 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4953363 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4542883 usd
us-gaap Net Income Loss
NetIncomeLoss
-410480 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4953363 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4345345 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-68735 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-4414080 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4161312 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4161312 usd
us-gaap Net Income Loss
NetIncomeLoss
-252768 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-4414080 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-4414080 usd
us-gaap Net Income Loss
NetIncomeLoss
-410480 usd
us-gaap Net Income Loss
NetIncomeLoss
-252768 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
8504 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
8505 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-27976 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
29894 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-45000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
261598 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
139464 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-112402 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-89693 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
30000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-82402 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-89693 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
112809 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
235311 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30407 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
145618 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-112402 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30407 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5765578 usd
CY2024Q3 BLNC Working Capital Deficit
WorkingCapitalDeficit
-4953363 usd
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2000 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_842_eus-gaap--UseOfEstimates_z56XUYo9sbte" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86E_z5ZmQTcZmeoj">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates may include those pertaining to stock-based compensation, depreciable lives of fixed assets and deferred tax assets. Actual results could materially differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q3 us-gaap Investment Owned Balance Shares
InvestmentOwnedBalanceShares
26573 shares
CY2024Q3 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
79936 usd
CY2024Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
3.22
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
27976 usd
CY2023Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 share for 8 share reverse stock split
CY2024Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 share for 2.5 reverse stock split
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zFU2BYtqxvQ2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86B_zNnFhlggpdX3">Concentration of Credit Risk</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and marketable securities. As of September 30, 2024, and December 31, 2023, the carrying value of marketable securities was $<span id="xdx_90D_eus-gaap--MarketableSecurities_iI_c20240930_zWvlBbIRw179" title="Marketable securities">79,936</span> and $<span id="xdx_908_eus-gaap--MarketableSecurities_iI_c20231231_z9LS1HEHP0zb" title="Marketable securities">107,912</span>, respectively. The securities are included in the Investment at Fair Value – Related Party on the consolidated balance sheets, which consist of common shares held in one (1) investment which currently is trading on the Over-the-Counter Bulletin Board (OTCBB).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Marketable Securities
MarketableSecurities
79936 usd
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
107912 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
3772 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
6786 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9980 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11316 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9980 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11316 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 BLNC Notes Receivable Unamortized Allowance Current Percentage
NotesReceivableUnamortizedAllowanceCurrentPercentage
1 pure
CY2024Q3 BLNC Notes Receivable Unamortized Allowance Current
NotesReceivableUnamortizedAllowanceCurrent
141000 usd

Files In Submission

Name View Source Status
0001493152-24-046598-index-headers.html Edgar Link pending
0001493152-24-046598-index.html Edgar Link pending
0001493152-24-046598.txt Edgar Link pending
0001493152-24-046598-xbrl.zip Edgar Link pending
blnc-20240930.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
blnc-20240930_cal.xml Edgar Link unprocessable
blnc-20240930_lab.xml Edgar Link unprocessable
blnc-20240930_def.xml Edgar Link unprocessable
blnc-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
form10-q_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending